Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties

Novo Nordisk A/S (NYSE:NVO) stock is down 5.3% to trade at $69.90 at last check, after the drugmaker's obesity drug CagriSema showed no clear advantage over Eli Lilly's (LLY) Zepbound. The company also noted it ended its partnership with Hims and Hers Health (NYSE:HIMS), which granted the latter direct access to its weight loss drug Wegovy via NovoCare Pharmacy.NVO is on track for its sixth-straight daily loss and pacing for its worst day since April 17. The shares are also now testing a familiar floor at t ...